Topspin Fund L.P. 4

Accession 0001104659-19-064691

CIK 0001673772other

View on SEC.gov Company Profile

Filed

Nov 14, 7:00 PM ET

Accepted

Nov 15, 2:52 PM ET

Size

18.4 KB

Accession

0001104659-19-064691

Insider Transaction Report

Form 4

Period: 2019-11-04

RAPT Therapeutics, Inc.RAPT

Topspin Fund L.P.

10% Owner

Transactions

Purchase
Common Stock
2019-11-04$12.00/sh+415,000$4,980,000→ 2,575,371 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2019-11-04−1,641,666→ 0 total(indirect: See footnotes 2, 3 and 4)
From: 2019-11-04→ Common Stock (1,641,666 underlying)
Conversion
Series C Preferred Stock
2019-11-04−363,504→ 0 total
From: 2019-11-04→ Common Stock (363,504 underlying)
Conversion
Series C-2 Preferred Stock
2019-11-04−155,201→ 0 total
From: 2019-11-04→ Common Stock (155,201 underlying)

Topspin Biotech Fund II, L.P.

10% Owner

Transactions

Purchase
Common Stock
2019-11-04$12.00/sh+415,000$4,980,000→ 2,575,371 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2019-11-04−1,641,666→ 0 total(indirect: See footnotes 2, 3 and 4)
From: 2019-11-04→ Common Stock (1,641,666 underlying)
Conversion
Series C Preferred Stock
2019-11-04−363,504→ 0 total
From: 2019-11-04→ Common Stock (363,504 underlying)
Conversion
Series C-2 Preferred Stock
2019-11-04−155,201→ 0 total
From: 2019-11-04→ Common Stock (155,201 underlying)

LG Management, LLC

10% Owner

Transactions

Purchase
Common Stock
2019-11-04$12.00/sh+415,000$4,980,000→ 2,575,371 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2019-11-04−1,641,666→ 0 total(indirect: See footnotes 2, 3 and 4)
From: 2019-11-04→ Common Stock (1,641,666 underlying)
Conversion
Series C Preferred Stock
2019-11-04−363,504→ 0 total
From: 2019-11-04→ Common Stock (363,504 underlying)
Conversion
Series C-2 Preferred Stock
2019-11-04−155,201→ 0 total
From: 2019-11-04→ Common Stock (155,201 underlying)

GUTHART LEO

10% Owner

Transactions

Purchase
Common Stock
2019-11-04$12.00/sh+415,000$4,980,000→ 2,575,371 total(indirect: See Footnote)
Conversion
Series B Preferred Stock
2019-11-04−1,641,666→ 0 total(indirect: See footnotes 2, 3 and 4)
From: 2019-11-04→ Common Stock (1,641,666 underlying)
Conversion
Series C Preferred Stock
2019-11-04−363,504→ 0 total
From: 2019-11-04→ Common Stock (363,504 underlying)
Conversion
Series C-2 Preferred Stock
2019-11-04−155,201→ 0 total
From: 2019-11-04→ Common Stock (155,201 underlying)

Footnotes (4)

[F1]Consists of (1) 1,641,666 shares held of record by Topspin Biotech Fund II, LP; and (ii) 933,705 shares held of record by Topspin Fund, LP. Each of Topspin Biotech Fund II, LP and Topspin Fund, LP disclaims beneficial ownership of the shares held of record by the other.
[F2]Each share of Series B, C and C-2 Preferred Stock shown in Column 5 converted into one share of Common Stock automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. Giving effect to such conversion, the ownership by the reporting persons of the shares of the Issuer's common stock is as set forth in Note 1 above.
[F3]1,641,666 of such shares are held directly by Topspin Biotech Fund II, L.P. LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.
[F4]933,705 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.

Documents

1 file

4
tv532611_4.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

RAPT Therapeutics, Inc.

CIK 0001673772

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001615782

Filing Metadata

Form type: 4
Filed: Nov 14, 7:00 PM ET
Accepted: Nov 15, 2:52 PM ET
Size: 18.4 KB

View on SEC.gov